180 related articles for article (PubMed ID: 36342850)
1. DNA-Encoded Library Screening To Inform Design of a Ribonuclease Targeting Chimera (RiboTAC).
Meyer SM; Tanaka T; Zanon PRA; Baisden JT; Abegg D; Yang X; Akahori Y; Alshakarchi Z; Cameron MD; Adibekian A; Disney MD
J Am Chem Soc; 2022 Nov; 144(46):21096-21102. PubMed ID: 36342850
[TBL] [Abstract][Full Text] [Related]
2. Methods for the study of ribonuclease targeting chimeras (RiboTACs).
Springer NA; Meyer SM; Taghavi A; Benhamou RI; Tong Y; Childs-Disney JL; Disney MD
Methods Enzymol; 2023; 692():249-298. PubMed ID: 37925183
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment.
Zhang P; Liu X; Abegg D; Tanaka T; Tong Y; Benhamou RI; Baisden J; Crynen G; Meyer SM; Cameron MD; Chatterjee AK; Adibekian A; Childs-Disney JL; Disney MD
J Am Chem Soc; 2021 Aug; 143(33):13044-13055. PubMed ID: 34387474
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-RIBOTAC Strategy Enabling Tumor-Specific Targeted Degradation of MicroRNA for Precise Cancer Therapy.
Fang Y; Wu Q; Wang F; Liu Y; Zhang H; Yang C; Zhu Z
Small Methods; 2024 May; ():e2400349. PubMed ID: 38794853
[TBL] [Abstract][Full Text] [Related]
5. Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs).
Haj-Yahia S; Nandi A; Benhamou RI
Expert Opin Drug Discov; 2023; 18(8):929-942. PubMed ID: 37306675
[TBL] [Abstract][Full Text] [Related]
6. Altering the Cleaving Effector in Chimeric Molecules that Target RNA Enhances Cellular Selectivity.
Suresh BM; Tong Y; Abegg D; Adibekian A; Childs-Disney JL; Disney MD
ACS Chem Biol; 2023 Nov; 18(11):2385-2393. PubMed ID: 37824291
[TBL] [Abstract][Full Text] [Related]
7. Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera.
Tong Y; Zhang P; Yang X; Liu X; Zhang J; Grudniewska M; Jung I; Abegg D; Liu J; Childs-Disney JL; Gibaut QMR; Haniff HS; Adibekian A; Mouradian MM; Disney MD
Proc Natl Acad Sci U S A; 2024 Jan; 121(2):e2306682120. PubMed ID: 38181056
[TBL] [Abstract][Full Text] [Related]
8. Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders.
Haniff HS; Tong Y; Liu X; Chen JL; Suresh BM; Andrews RJ; Peterson JM; O'Leary CA; Benhamou RI; Moss WN; Disney MD
ACS Cent Sci; 2020 Oct; 6(10):1713-1721. PubMed ID: 33140033
[TBL] [Abstract][Full Text] [Related]
9. Targeted Degradation of the Oncogenic MicroRNA 17-92 Cluster by Structure-Targeting Ligands.
Liu X; Haniff HS; Childs-Disney JL; Shuster A; Aikawa H; Adibekian A; Disney MD
J Am Chem Soc; 2020 Apr; 142(15):6970-6982. PubMed ID: 32233464
[TBL] [Abstract][Full Text] [Related]
10.
Tong Y; Gibaut QMR; Rouse W; Childs-Disney JL; Suresh BM; Abegg D; Choudhary S; Akahori Y; Adibekian A; Moss WN; Disney MD
J Am Chem Soc; 2022 Jul; 144(26):11620-11625. PubMed ID: 35737519
[TBL] [Abstract][Full Text] [Related]
11. DNA-encoded library versus RNA-encoded library selection enables design of an oncogenic noncoding RNA inhibitor.
Benhamou RI; Suresh BM; Tong Y; Cochrane WG; Cavett V; Vezina-Dawod S; Abegg D; Childs-Disney JL; Adibekian A; Paegel BM; Disney MD
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110406
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule screening of ribonuclease L binders for RNA degradation.
Borgelt L; Haacke N; Lampe P; Qiu X; Gasper R; Schiller D; Hwang J; Sievers S; Wu P
Biomed Pharmacother; 2022 Oct; 154():113589. PubMed ID: 36029542
[TBL] [Abstract][Full Text] [Related]
13. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA.
Costales MG; Suresh B; Vishnu K; Disney MD
Cell Chem Biol; 2019 Aug; 26(8):1180-1186.e5. PubMed ID: 31130520
[TBL] [Abstract][Full Text] [Related]
14. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.
D'Avino C; Palmieri D; Braddom A; Zanesi N; James C; Cole S; Salvatore F; Croce CM; De Lorenzo C
Oncotarget; 2016 Dec; 7(52):87016-87030. PubMed ID: 27894092
[TBL] [Abstract][Full Text] [Related]
15. G-Quadruplex mRNAs Silencing with Inducible Ribonuclease Targeting Chimera for Precision Tumor Therapy.
Zhang Y; Wang L; Wang F; Chu X; Jiang JH
J Am Chem Soc; 2024 Jun; ():. PubMed ID: 38832857
[TBL] [Abstract][Full Text] [Related]
16. Design of a small molecule against an oncogenic noncoding RNA.
Velagapudi SP; Cameron MD; Haga CL; Rosenberg LH; Lafitte M; Duckett DR; Phinney DG; Disney MD
Proc Natl Acad Sci U S A; 2016 May; 113(21):5898-903. PubMed ID: 27170187
[TBL] [Abstract][Full Text] [Related]
17. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
18. Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype.
Li Y; Disney MD
ACS Chem Biol; 2018 Nov; 13(11):3065-3071. PubMed ID: 30375843
[TBL] [Abstract][Full Text] [Related]
19. Optimization of a Protein-Targeted Medicine into an RNA-Specific Small Molecule.
Meyer SM; Tanaka T; Taghavi A; Baisden JT; Grefe M; Disney MD
ACS Chem Biol; 2023 Nov; 18(11):2336-2342. PubMed ID: 37870980
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-137 Inhibits Cancer Progression by Targeting Del-1 in Triple-Negative Breast Cancer Cells.
Lee SJ; Jeong JH; Kang SH; Kang J; Kim EA; Lee J; Jung JH; Park HY; Chae YS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
